Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102


Connect MM Registry as a national reference for United States multiple myeloma patients.

Ailawadhi S, Jagannath S, Narang M, Rifkin RM, Terebelo HR, Toomey K, Durie BGM, Hardin JW, Gasparetto CJ, Wagner L, Omel JL, Kumar V, Yue L, Kitali A, Agarwal A, Abonour R; Connect MM Registry Investigators.

Cancer Med. 2019 Nov 7. doi: 10.1002/cam4.2656. [Epub ahead of print]


Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J.

Blood Adv. 2019 Oct 22;3(20):2986-2994. doi: 10.1182/bloodadvances.2019000308.


Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.

Ailawadhi S, Medhekar R, Princic N, Fowler R, Tran O, Bhowmik D, Panjabi S.

J Oncol Pharm Pract. 2019 Oct 20:1078155219881489. doi: 10.1177/1078155219881489. [Epub ahead of print]


Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM.

Leuk Lymphoma. 2019 Oct 16:1-9. doi: 10.1080/10428194.2019.1672052. [Epub ahead of print]


Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.

Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M.

Blood Cancer J. 2019 Sep 30;9(10):75. doi: 10.1038/s41408-019-0237-1.


Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.

Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S.

Clin Lung Cancer. 2019 Aug 30. pii: S1525-7304(19)30254-2. doi: 10.1016/j.cllc.2019.08.005. [Epub ahead of print]


Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R.

Anticancer Drugs. 2019 Sep;30(8):859-865. doi: 10.1097/CAD.0000000000000810.


Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.

Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):619-623. doi: 10.1016/j.clml.2019.06.010. Epub 2019 Jun 26.


Updates in prognostication and treatment of Waldenström's macroglobulinemia.

Advani P, Paulus A, Ailawadhi S.

Hematol Oncol Stem Cell Ther. 2019 May 28. pii: S1658-3876(19)30041-X. doi: 10.1016/j.hemonc.2019.05.002. [Epub ahead of print] Review.


Survival trends in glioblastoma and association with treating facility volume.

Aulakh S, DeDeo MR, Free J, Rosenfeld SS, Quinones-Hinojosa A, Paulus A, Manna A, Manochakian R, Chanan-Khan AA, Ailawadhi S.

J Clin Neurosci. 2019 Oct;68:271-274. doi: 10.1016/j.jocn.2019.04.028. Epub 2019 May 24.


Many Shades of Disparities in Myeloma Care.

Ganguly S, Mailankody S, Ailawadhi S.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:519-529. doi: 10.1200/EDBK_238551. Epub 2019 May 17. Review.


Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.

Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A.

Clin Cancer Res. 2019 Jul 1;25(13):3974-3985. doi: 10.1158/1078-0432.CCR-18-3412. Epub 2019 Apr 2.


Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.


Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.

Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R.

Clin Ther. 2019 Mar;41(3):477-493.e7. doi: 10.1016/j.clinthera.2019.01.009. Epub 2019 Feb 14.


Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia.

Khurana S, Ahmed S, Alegria VR, Aulakh S, Ailawadhi M, Singh A, Chanan-Khan A, Ailawadhi S.

SAGE Open Med Case Rep. 2019 Jan 16;7:2050313X18823917. doi: 10.1177/2050313X18823917. eCollection 2019.


Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG.

Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8.


A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin.

Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T.

J Gastrointest Oncol. 2018 Dec;9(6):1063-1073. doi: 10.21037/jgo.2018.07.09.


Predictors of palliative treatment in stage IV colorectal cancer.

Osagiede O, Spaulding AC, Frank RD, Merchea A, Uitti R, Ailawadhi S, Kelley S, Colibaseanu D.

Am J Surg. 2019 Sep;218(3):514-520. doi: 10.1016/j.amjsurg.2018.12.016. Epub 2018 Dec 14.


Commentary: Race and Ethnicity in Biomedical Research - Classifications, Challenges, and Future Directions.

Idossa D, Duma N, Chekhovskiy K, Go R, Ailawadhi S.

Ethn Dis. 2018 Oct 18;28(4):561-564. doi: 10.18865/ed.28.4.561. eCollection 2018 Fall.


A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.


Supplemental Content

Loading ...
Support Center